ReviewFrontiers of medicine2018
Innate and adaptive T cells in influenza disease.
Review in Frontiers of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- T-cell receptor repertoires as potential diagnostic markers for patients with COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Trial
- Research trends and key contributors in studies on influenza vaccines for children: A 20-year bibliometric analysis.Human vaccines & immunotherapeutics · 2025Article
- Review
- Research Progress of Universal Influenza Vaccine.Vaccines · 2025Review
- Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses.Scientific reports · 2025Article
- Adjuvant-free, self-assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses.Frontiers in immunology · 2025Article
- DNA and protein-generated chimeric molecules for delivery of influenza viral epitopes in mouse and humanized NSG transfer models.Human vaccines & immunotherapeutics · 2024Review
- Immune Response to Respiratory Viral Infections.International journal of molecular sciences · 2024Review
- Review
- SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments.Microorganisms · 2023Review
- No association found between late-onset inflammatory adverse events after soft tissue filler injections and the adaptive immune system.Journal of cosmetic dermatology · 2023Article
- The gut-lung axis in influenza A: the role of gut microbiota in immune balance.Frontiers in immunology · 2023Review
- Role of hormones in the pregnancy and sex-specific outcomes to infections with respiratory viruses.Immunological reviews · 2022Review
- HLA-A*11:01-restricted CD8+ T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people.PLoS pathogens · 2022Article
- Evaluation of Human Circulating T Follicular Helper Cells in Influenza- and SARS-CoV-2-Specific B Cell Immunity.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Screening of crosstalk and pyroptosis-related genes linking periodontitis and osteoporosis based on bioinformatics and machine learning.Frontiers in immunology · 2022Article
- Anti-Interferon-γ Autoantibodies Impair T-Lymphocyte Responses in Patients withInfection and drug resistance · 2022Article
- Designing spatial and temporal control of vaccine responses.Nature reviews. Materials · 2022Review
- In quest of a new therapeutic approach in COVID-19: the endocannabinoid system.Drug metabolism reviews · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza is a major global health problem, causing infections of the respiratory tract, often leading to acute pneumonia, life-threatening complications and even deaths. Over the last seven decades, vaccination strategies have been utilized to protect people from complications of influenza, especially groups at high risk of severe disease. While current vaccination regimens elicit strain-specific antibody responses, they fail to generate cross-protection against seasonal, pandemic and avian viruses. Moreover, vaccines designed to generate influenza-specific T-cell responses are yet to be optimized. During natural infection, viral replication is initially controlled by innate immunity before adaptive immune responses (T cells and antibody-producing B cells) achieve viral clearance and host recovery. Adaptive T and B cells maintain immunological memory and provide protection against subsequent infections with related influenza viruses. Recent studies also shed light on the role of innate T-cells (MAIT cells, γδ cells, and NKT cells) in controlling influenza and linking innate and adaptive immune mechanisms, thus making them attractive targets for vaccination strategies. We summarize the current knowledge on influenza-specific innate MAIT and γδ T cells as well as adaptive CD8
Indexed as
Identifiers
29352371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.